ObjectiveTo investigate the clinical effect of dapagliflozin combined with α-lipoic acid for treating patients with type 2 diabetes mellitus. MethodsA total of 86 patients with type 2 diabetes mellitus treated in our hospital from May 2019 to May 2020 were selected as the research objects, and they were divided into observation group and control group by the random number method, with 43 cases in each group. Patients in the control group were orally administrated with dapagliflozen, based on which the patients in the observation group were given α-lipoic acid injection treatment, for a course of 3 months. The clinical therapeutic effects of the two groups were compared. The blood glucose levels, oxidative stress levels and islet function were examined and compared between the two groups before and after treatment. ResultsThe total effective rate in the observation group (95.34%) was significantly higher than that in the control group (81.39%), with a statistically significant difference (P＜0.05). Before the treatment, there was no statistically significant difference in blood glucose levels between both groups (P＞0.05). After 3 months of treatment, the levels of fasting blood glucose (FPG), glycosylated hemoglobin (HbA1c) and 2h postprandial blood glucose (2hPG) in both groups significantly decreased, and the levels in the observation group were prominently lower than those in the control group, with statistically significant differences (P＜0.05). Before the treatment, there were no statistically significant differences in the levels of malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione peroxidase (GPx) between the two groups. After 3 months of treatment, the level of MDA in both groups significantly decreased, while the levels of SOD and GPx significantly increased. Patients in the observation group had prominently lower level of MDA and higher levels of SOD and GPX than the control group, and the differences were considered statistically significant (P＜0.05). Before the treatment, there were no statistically significant differences in islet beta cell function index (HOMA-β), fasting insulin and C-peptide levels between both groups (P＞0.05). After 3 months of treatment, the HOMA-β, fasting insulin and C-peptide levels of both groups significantly increased， and the levels of the observation group were significantly higher than those of the control group, with statistically significant differences (P＜0.05). ConclusionDapagliflozin combined with α-lipoic acid injection has significant clinical effect on patients with type 2 diabetes mellitus, which can effectively decrease the levels of blood glucose and oxidative stress of patients, and significantly improve the islet function of patients.

无